The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Is The Market Value Of The Histone Deacetylase Inhibitors Market Projected To Expand During 2026–2030?
The histone deacetylase inhibitors market has experienced significant growth in recent years. Its size is anticipated to expand from $1.29 billion in 2025 to $1.39 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.6%. This historical expansion can be attributed to several factors, including the early success of HDAC inhibitors in hematological malignancies, a deeper understanding of epigenetic regulation in disease, the availability of approved first-generation HDAC inhibitors, the broadening of cancer research infrastructure, and increased investment in targeted cancer therapies.
The market for histone deacetylase inhibitors is projected to experience robust expansion over the coming years. It is anticipated to reach $1.81 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.8%. This anticipated growth during the forecast period is primarily driven by factors such as the increasing global prevalence of cancer, an expanding array of epigenetic-based therapies under development, a heightened emphasis on personalized oncology strategies, the broadening scope of clinical trials for neurological and inflammatory conditions, and a clear need for more selective and safer epigenetic medications. Key trends expected within this period encompass the escalating integration of HDAC inhibitors into cancer treatment plans, a heightened emphasis on developing selective and isoform-specific HDAC inhibitors, the increasing implementation of combination therapies featuring HDAC inhibitors, the broadening exploration of HDAC inhibitor research beyond their traditional cancer applications, and consistent progress in the development of oral HDAC inhibitor formulations.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17170&type=smp
Which Growth Drivers Are Expected To Support The Histone Deacetylase Inhibitors Market Forward?
The rising occurrence of cancer is projected to fuel the future expansion of the histone deacetylase inhibitors market. This escalating cancer incidence is predominantly linked to aging populations, increased exposure to risk factors such as tobacco, diet, and environmental pollutants, coupled with enhanced diagnostic techniques that enable earlier and more frequent detection. Histone deacetylase inhibitors address cancer by modifying chromatin structure, leading to the activation of tumor suppressor genes and the suppression of oncogenes, thereby prompting cell cycle arrest and apoptosis in cancerous cells. For example, in February 2024, the World Health Organization, a US-based intergovernmental organization, estimated that new cancer cases would total approximately 35 million in 2050, representing a 77% increase from the roughly 20 million cases recorded in 2022. Thus, the growing incidence of cancer is a significant factor driving the growth of the histone deacetylase inhibitors market.
How Are Different Segment Groups Identified Within The Histone Deacetylase Inhibitors Market?
The histone deacetylase inhibitors market covered in this report is segmented –
1) By Classification: Class I Histone Deacetylases (HDACs), Class II Histone Deacetylases (HDACs), Class III Histone Deacetylases (HDACs), Other Classifications
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Oncology, Neurology, Other Applications
5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Class I Histone Deacetylases (HDACs): HDAC1 Inhibitors, HDAC2 Inhibitors, HDAC3 Inhibitors, HDAC8 Inhibitors
2) By Class II Histone Deacetylases (HDACs): HDAC4 Inhibitors, HDAC5 Inhibitors, HDAC6 Inhibitors, HDAC7 Inhibitors, HDAC9 Inhibitors, HDAC10 Inhibitors
3) By Class III Histone Deacetylases (HDACs): Sirtuin 1 (SIRT1) Inhibitors, Sirtuin 2 (SIRT2) Inhibitors, Sirtuin 3 (SIRT3) Inhibitors, Sirtuin 4 (SIRT4) Inhibitors, Sirtuin 5 (SIRT5) Inhibitors, Sirtuin 6 (SIRT6) Inhibitors, Sirtuin 7 (SIRT7) Inhibitors
4) By Other Classifications: Dual-acting HDAC Inhibitors, Pan-HDAC Inhibitors, Selective HDAC Inhibitors, Combination Inhibitors (HDAC + Other Mechanisms)
Which Trends Are Contributing To Changes In The Histone Deacetylase Inhibitors Market?
Major companies operating in the histone deacetylase inhibitors market are concentrating on developing innovative product formulations, such as oral histone deacetylase (HDAC) inhibitors, to broaden treatment options and enhance patient convenience and compliance. An oral histone deacetylase (HDAC) inhibitor is a medication taken by mouth that targets HDAC enzymes crucial for gene regulation, with potential applications in treating various diseases, including cancer and inflammatory conditions. For instance, in March 2024, Italfarmaco S.p.A., an Italy-based pharmaceutical company, secured Food and Drug Administration approval for Duvyzat (givinostat), an oral histone deacetylase (HDAC) inhibitor, for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 6 years and older. Duvyzat, as a histone deacetylase (HDAC) inhibitor, works to mitigate the sequence of events leading to muscle damage, potentially slowing the progression of muscle deterioration associated with DMD by inhibiting HDAC overactivity, thereby reducing inflammation and fibrosis while promoting muscle fiber regeneration. The approval stems from the pivotal phase 3 EPIDYS trial, which met its primary endpoint, demonstrating that patients on Duvyzat showed a statistically significant decrease in the time to complete the four-stair climb assessment compared to placebo.
Which Organizations Are Involved In The Histone Deacetylase Inhibitors Market?
Major companies operating in the histone deacetylase inhibitors market are Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Shenzhen Chipscreen Biosciences Co. Ltd., Celgene Corporation, Spectrum Pharmaceuticals Inc., Curis Inc., Onxeo SA, Celleron Therapeutics, Forum Pharmaceuticals Inc., Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Karyopharm Therapeutics Inc., Medivir AB, Huya Bioscience International LLC, Crystal Genomics Inc., Midatech Pharma PLC, Regenacy Pharmaceuticals Inc.
Access The Complete Histone Deacetylase Inhibitors Market Report:
Which Region Has The Strongest Presence In The Histone Deacetylase Inhibitors Market?
North America was the largest region in the histone deacetylase inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Histone Deacetylase Inhibitors Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=17170&type=smp
Browse Through More Reports Similar to the Global Histone Deacetylase Inhibitors Market 2026, By The Business Research Company
Histone Deacetylase Inhibitors Market Report 2026
Histone Deacetylase Inhibitors Market Report 2026
Enzyme Inhibitor Market Report 2026
https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model